Switch to: References

Add citations

You must login to add citations.
  1. COVID-19 human challenge trials and randomized controlled trials: lessons for the next pandemic.Charles Weijer - forthcoming - Research Ethics.
    The COVID-19 pandemic touched off an unprecedented search for vaccines and treatments. Without question, the development of vaccines to prevent COVID-19 was an enormous scientific accomplishment. Further, the RECOVERY and Solidarity trials identified effective treatments for COVID-19. But all was not success. The urgent need for COVID-19 prevention and treatment fueled an embrace of risks—to research participants and to the reliability of the science itself—as allegedly necessary costs to speed scientific progress. Scientists and (even) ethicists supported overturning longstanding norms protecting (...)
    Download  
     
    Export citation  
     
    Bookmark  
  • Treatment effectiveness, generalizability, and the explanatory/pragmatic-trial distinction.Steven Tresker - 2022 - Synthese 200 (4):1-29.
    The explanatory/pragmatic-trial distinction enjoys a burgeoning philosophical and medical literature and a significant contingent of support among philosophers and healthcare stakeholders as an important way to assess the design and results of randomized controlled trials. A major motivation has been the need to provide relevant, generalizable data to drive healthcare decisions. While talk of pragmatic and explanatory trials could be seen as convenient shorthand, the distinction can also be seen as harboring deeper issues related to inferential strategies used to evaluate (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • Uses of equipoise in discussions of the ethics of randomized controlled trials of COVID-19 therapies.Charles Weijer & Hayden P. Nix - 2021 - BMC Medical Ethics 22 (1):1-8.
    BackgroundEarly in the COVID-19 pandemic, the urgent need to discover effective therapies for COVID-19 prompted questions about the ethical problem of randomization along with its widely accepted solution: equipoise. In this scoping review, uses of equipoise in discussions of randomized controlled trials of COVID-19 therapies are evaluated to answer three questions. First, how has equipoise been applied to COVID-19 research? Second, has equipoise been employed accurately? And third, do concerns about equipoise pose a barrier to the ethical conduct of COVID-19 (...)
    Download  
     
    Export citation  
     
    Bookmark   1 citation